compani
revenu provid recast sale
adj ep provid recast ep exclud
 time pausedowngrad neutral
messag view best long-term growth profil us pharma
growth broad consensu believ larg price stock given
ev/ebit premium group believ manag done impress
job deliv see limit upsid competit novo
semaglutid franchis overal immunolog portfolio fulli understood
result downgrad neutral remov price target
estim fair valu rang
still posit lli diabet growth asset captur increment
investor mindshar post-ada like challeng expect updat ada
american diabet associ broadli posit includ gip/glp titrat
toler data well full data rewind glp class overal
continu gain mindshar among physician rewind pioneer
novo b-cse buy dkk cement cardiovascular benefit
interest us potenti class increasingli domin
jardianc see new growth inflect wake posit credenc studi data
jnj cs invokana inhibitor recal credenc stop
earli juli evid benefit primari composit endpoint progress
end-stag kidney diseas time dialysi kidney transplant doubl serum
creatinin renal cardiovascular cv death use addit standard
care notabl patient type diabet chronic kidney diseas
result present april isn/wcn world congress nephrolog
meet et accompani live webcast
stream prior result diminish return blood sugar target treat
diabet patient ckd physician switch patient agent
physician weve spoken highlight well pre-specifi exploratori analysi
jardianc cv outcom studi empa-reg show reduct
progress kidney diseas reason inhibitor could see use
everi diabet patient renal insuffici whether data potenti
resurrect jnj invokana reintroduc competitor jardianc like depend
credenc studi abil exoner drug safeti question present
jardianc forecast assum biggest beneficiari class acceler
strong run posit news limit impact competitor
futur growth larg reflect stock view despit
posit factor updat model assumpt above-consensu
sale trulic jardianc overal consensu sale ep forecast
forecast point posit view street lli
oncolog legaci insulin franchis near- medium term well sustain
margin improv view insulin growth appear overst consensu
san-par neutral admelog begin take meaning share fast-act
insulin share market one year still gain overal growth trend
arent great verzenio group risk olumi multipl new entrant
may underst our/street number given competit oral jak program late-
stage develop highest multipl decad trade
premium biopharma peer ev/ebit respect believ lli
growth larg reflect stock
physician increasingli mix tanezumab prospect lower sale
estim tanezumab demonstr statist signific improv pain
score osteoarthr chronic lower back pain outstand question drug
risk/benefit profil tanezumab given risk rapidli progress osteoarthr
page analyst certif import disclosur
rpoa observ tanezumab-tr patient date narrow efficaci window
seen detail phase osteoarthr data acr placebo appear
perform better earlier studi pain specialist weve spoken mix util
respons rang narrow label limit use broader use slow uptak
given safeti concern result cut estim
page analyst certif import disclosur
valuat risk
fair valu rang reflect forecast sale profit
use larg pharmaceut compani discount rate termin
upsid risk valuat includ trulic jardianc sale meaning
estim better expect oper leverag
downsid risk includ sustain price pressur diabet immunolog higher-
than-expect rate seriou advers event rpoa long-term safeti studi tanezumab
detail data disclos
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
